NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.
Last trade$4.39
Day change-$0.15 (-3.30%)
Day range$4.36 – $5.16
Volume201,401
Market cap$131M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$130.98M
Price / earnings
—
Price / book
-9.94×
Price / sales
—
EV / sales
—
EV / EBITDA
-3.07×
Profitability
Earnings per share
-$1.59
Return on assets
-492.87%
Return on equity
348.14%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-0×
Current ratio
0.38×
Quick ratio
0.38×
Cash ratio
0.28×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$20.94M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for NTHI, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Revenue
$0
$0
$0
$0
$0
$0
$39.99K
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$39.99K
Selling, general and administrative
$1.8M
$7.83M
$4.41M
$24.19M
$6.22M
$5.03M
$19.2M
Research and development
$1.31M
$2.65M
$1.29M
$1.25M
$715.04K
$677.33K
$998.22K
Total operating expenses
$5.83M
$14.07M
$7.06M
$13.7M
$6.93M
$5.71M
$31.94M
Operating income
-$5.83M
-$14.07M
-$7.06M
-$13.7M
-$6.93M
-$5.71M
-$31.9M
Interest expense
-$97.51K
-$402.32K
-$982.62K
-$478.77K
-$869.82K
-$241K
-$308.92K
Income before taxes
-$4.44M
-$14.24M
-$8.82M
-$15.52M
-$8.62M
-$5.68M
-$32.33M
Income taxes
$0
$0
$0
$0
$0
$0
$0
Net income
-$4.44M
-$14.24M
-$8.82M
-$15.52M
-$8.62M
-$5.68M
-$32.33M
Net income attributable to common shareholders
-$7.27M
-$14.24M
-$8.82M
-$15.52M
-$8.62M
-$5.68M
-$32.33M
EBITDA
-$5.83M
-$14.06M
-$7.04M
-$13.7M
-$6.93M
-$5.71M
-$31.9M
Basic earnings per share
-$0.28
-$0.58
-$0.38
-$0.73
-$0.45
-$0.30
-$1.78
Diluted earnings per share
-$0.28
-$0.58
-$0.38
-$0.73
-$0.45
-$0.30
-$1.78
Recent news
Company coverage with links to the original publishers.
Four biotechnology companies presented clinical findings and emerging treatment approaches for brain cancers at the 31st Annual Meeting of the Society for Neuro-Oncology in Philadelphia. NeOnc Technologies is preparing for FDA meetings on two programs (NEO100 and NEO212), Cerenome is advancing REYOBIQ therapy and diagnostic tools, Nuvation Bio is expanding data on safusidenib for IDH1-mutant gliomas, and Jazz Pharmaceuticals is progressing dordaviprone through Phase 3 trials for rare brain cancers.
NeOnc Technologies Holdings (NASDAQ: NTHI), a clinical-stage biopharmaceutical company, will present data from two investigational brain cancer programs—intranasal NEO100 and oral NEO212—at the Society for Neuro-Oncology annual meeting on November 13, 2026. The company is advancing ambitious plans for a 500-patient international clinical trial across 30 hospitals in three countries, leveraging innovative drug delivery approaches and AI-assisted tumor modeling technology.
Global cancer research is advancing through AI-supported precision medicine, biomarker-guided treatments, and innovative approaches. Anthropic is supporting pediatric cancer care through the PCX program, while companies like AstraZeneca report survival improvements in gastric cancer with sonesitatug vedotin. Researchers in Japan and South Korea are exploring novel approaches including using cancer cells' own chemistry to produce treatments and reprogramming cancer cells toward normal states.
NeOnc Technologies announced early clinical improvements in a critically ill three-year-old boy treated with investigational intranasal NEO100 through its Compassionate Care program in Abu Dhabi. The patient is now breathing independently without ventilator support and showing renewed leg movement. The company emphasized these observations involve a single patient and do not establish efficacy or predict outcomes in other patients.
NeOnc Technologies announced the appointment of Ali Alabedin, Head of Islamic Banking Group at First Abu Dhabi Bank, to its Board of Directors effective October 9, 2026. The appointment strengthens financial governance as NeOnc advances its clinical programs and expands operations in Abu Dhabi. The Department of Health – Abu Dhabi has granted IND authorization for NEO212, supporting Phase 2 development in the UAE.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.